# Luminopia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/luminopia

- Industry: Software
- Headquarters: Cambridge, US
- Website: www.luminopia.com
- Total disclosed funding: $20M
- Latest round: Series A (Jun 16, 2023)
- Investors on record: 6

## About

Based in Massachusetts, US, and founded in 2015 by its CEO Scott Xiao, and co-founders Alex Wendland, Dean Travers, and Raphael Rouvinov, Luminopia, Inc. operates as a healthcare technology company dedicated to amblyopia treatment for children aged 4-7. In June 2023, Luminopia, Inc. raised USD 15.81 in series A funding led by US Venture Partners, with participation from Broadfin Capital. ShangBay Capital and Vertical Group also participated in the round.   

Luminopia, Inc. offers content streaming software that can be integrated with commercially available Head-Mounted Displays (HMDs) c. It is suitable for both previously treated and untreated patients as well as employ a dual-action mechanism to modify visual content in real-time, presenting it differently to each eye. The therapy effectively combines stronger eye contrast reduction to overcome suppression and dichoptic masking to encourage the brain's integration of input from both eyes.

The company plans to use the series A funding to support the rollout of its product in late 2023 and make its therapy available to patients across the U.S.

## Funding rounds

- Series A, Jun 16, 2023, $16M — US Venture Partners, Vertical Group, Broadfin Capital, ShangBay Capital
- Seed, Oct 5, 2022, $4.1M — Vertical Group, Sony Innovation Fund, ShangBay Capital, SSI Strategy Holdings LLC

## Investors

- Vertical Group (https://capitalatlas.ai/funds/vertical-group) — Seed, Series A
- Sony Innovation Fund (https://capitalatlas.ai/funds/sony-innovation-fund) — Seed
- ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Seed, Series A
- SSI Strategy Holdings LLC — Seed
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series A
- Broadfin Capital — Series A